The Value of Stillness
Health Care: Drugs
Gilead Sciences Inc (GILD: NASDAQ)
$51.94 0.91 | 1.78%
06/18/13 - 04:00 PM ET
6.78M / 12.25M
Vol / Avg. Vol:50.87 / 51.03
Open / Prev. Close:50.87 - 52.05
Today's Range:24.80 - 58.07
52 Wk Range:42.22%
Performance YTD:TheStreet Rating:
Portfolios with GILD
- Portfolio NameUser Type
- UserDC
- ContributorMost-Active Stocks for the ...
- ProHighbridge Capital Management
- ProSteven Cohen - SAC Capital
- ProJohn Griffin - Blue Ridge C...
- UserMike Fatah's Mega Stock Por...
- UserRenzo's portfolio
- ContributorDrugs Facing FDA Approval i...
- UserGFNN Stockdiagnostics 23
- UserBender
Latest GILD Headlines from TheStreet
- Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard 06.17.13 | 05:06 pm
- Biotech Stock Mailbag: Exact Sciences, Questcor, Biotech M&A, Celsion 06.14.13 | 07:06 am
- Vertex's Roadmap to $10 Billion in Cystic Fibrosis Drug Sales 06.11.13 | 09:06 am
- Winners And Losers in CLL at ASCO '13 06.10.13 | 07:06 am
- Gilead Sciences Inc (GILD): Today's Featured Drugs Winner 06.07.13 | 05:06 pm
- Cramer: The Market Welcomes the Jobs Number 06.07.13 | 12:06 pm
- Gilead Sciences Inc Stock Buy Recommendation Reiterated (GILD) 06.07.13 | 10:06 am
- June 14th Options Now Available For Gilead Sciences 06.06.13 | 10:06 am
- CELG, AMGN, GILD, JNJ And PFE, Pushing Drugs Industry Downward 06.04.13 | 01:06 pm
- Cramer's 'Mad Money' Recap: Out With the New 06.03.13 | 08:06 pm
Press Releases for GILD
- Gilead Announces Update On Phase 3 Study Of Oral Fixed-Dose Combination Of Sofosbuvir And Ledipasvir For Genotype 1 Hepatitis C Patients - Business Wire 03.26.13 | 08:03 am
- European CHMP Adopts Positive Opinion For Stribild®, A Once-Daily, Integrase Inhibitor-Based, Single Tablet Regimen For The Treatment Of HIV-1 Infection - Business Wire 03.22.13 | 08:03 am
- Gilead’s Ranexa® Reduces Angina Frequency In Study Of Chronic Angina Patients With Type 2 Diabetes - Business Wire 03.10.13 | 02:03 pm
- Gilead Announces Full 24-Week Phase 2 Results For Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF) - Business Wire 03.05.13 | 12:03 pm
- Gilead Sciences To Present At The Cowen & Company 33rd Annual Health Care Conference On Monday, March 4 - Business Wire 03.01.13 | 04:03 pm
- Gilead Sciences To Present At Two Upcoming Investor Conferences - Business Wire 02.25.13 | 04:02 pm
- Gilead And Teva Reach Settlement Agreement In Viread® Patent Litigation - Business Wire 02.19.13 | 11:02 pm
- Gilead’s Sofosbuvir For Hepatitis C Meets Primary Endpoint In Fourth Pivotal Phase 3 Study - Business Wire 02.19.13 | 08:02 am
- Gilead Issues A Voluntary Recall Of One Lot Of Vistide® (Cidofovir Injection) Due To Presence Of Particulate Matter - Business Wire 02.15.13 | 06:02 pm
- Gilead Sciences To Present At Two Upcoming Investor Conferences - Business Wire 02.11.13 | 04:02 pm
Partner Headlines for GILD
- Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB) - Benzinga 06.12.13 | 01:06 pm
- 3 Impressive Biotech ETFs Crushing the Market - ETF News And Commentary - Zacks 06.11.13 | 03:06 pm
- Big Cap 20 Outperforming S&P 500, IBD 50 Too - Investor's Business Daily 06.10.13 | 06:06 pm
- Priority Review for Gilead Drug - Analyst Blog - Zacks 06.10.13 | 02:06 pm
- Enzon Pharmaceuticals, Inc. (ENZN) Ex-Dividend Date Scheduled for June 05, 2013 - NASDAQ 06.04.13 | 01:06 pm
- Stocks Rebound To End Higher; GII Jumps After Hours - Investor's Business Daily 06.03.13 | 05:06 pm
- Stock Market Closes Higher As Indexes Erase Losses - Investor's Business Daily 06.03.13 | 04:06 pm
- Stock Market News for June 3, 2013 - Market News - Zacks 06.03.13 | 03:06 pm
- Stocks Mixed In Late Trade; Stratasys, 3D Plunge - Investor's Business Daily 06.03.13 | 03:06 pm
- Stocks Slip Into Mixed Action; Alexion, Biogen, Gilead Tumble - Investor's Business Daily 06.03.13 | 12:06 pm
